TABLE 2

Comparison of Neonatal Morbidities and Therapies

ELBW GroupELGA Group
Period 1 (1996–1999) (n = 122)Period 2 (2000–2003) (n = 109)PPeriod 1 (1996–1999) (n = 118)Period 2 (2000–2003) (n = 107)P
Neonatal morbidity
    Intraventricular hemorrhage, n (%)
        None69 (57)81 (74).010a67 (57)78 (73).017a
        Grade I–II36 (30)19 (17)34 (29)20 (19)
        Grade III–IV17 (14)9 (8)17 (14)9 (8)
    Periventricular leukomalacia, n (%)10 (8)7 (6).60610 (8)7 (7).584
    Ventriculomegaly at discharge, n (%)16 (13)8 (7).15116 (14)8 (7).140
    Severe cranial ultrasound abnormality, n (%)b31 (25)14 (13).01630 (25)14 (13).020
    Sepsis, n (%)66 (54)57 (52).78460 (51)57 (53).716
    Meningitis, n (%)10 (8)3 (3).0737 (6)3 (3).339
    Necrotizing enterocolitis, n (%)5 (4)9 (8).1866 (5)8 (7).458
    PDA, n (%)82 (67)81 (74).23778 (66)79 (74).207
    Indirect bilirubin level, mean ± SD, mg/dL7.5 ± 2.47.3 ± 2.5.5527.7 ± 2.57.4 ± 2.6.379
Hospitalization, median (range), d109 (49–277)111 (68–329).183107 (49–277)111 (74–329).088
Therapies
    Surfactant treatment, n (%)108 (89)108 (99).001102 (86)105 (98).001
    Indomethacin therapy, n (%)c70 (57)87 (80)<.00165 (55)85 (79)<.001
    Surgical ligation for PDA, n (%)33 (27)43 (39).04531 (26)43 (40).027
    Duration of continuous positive airway pressure treatment, mean ± SD, dd15.3 ± 10.218.8 ± 11.5.01615.0 ± 9.818.8 ± 11.3.010
    Duration of ventilator dependence, median (range), d37 (2–86)43 (3–180).06436 (2–86)43 (3–180).020
    Total duration of oxygen therapy, median (range),de110 (63–688)104 (56–727).373106 (63–688)102 (64–727).445
    Postnatal steroid therapy, n (%)93 (76)33 (30)<.00188 (75)31 (29)<.001
    Duration of postnatal steroid therapy, median (range), df25 (2–120)8 (2–39)<.00125 (2–102)8 (2–39)<.001
  • a Cochran-Armitage test.

  • b Including grade III or IV intraventricular hemorrhage, periventricular leukomalacia, and ventriculomegaly at discharge.

  • c Prophylaxis or treatment for PDA.

  • d For those who received continuous positive airway pressure therapy.

  • e Including oxygen administered after discharge in the home.

  • f Excluding infants who did not receive postnatal steroid therapy.